Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ) just unveiled an announcement.
Shin Nippon Biomedical Laboratories, Ltd. announced a year-end dividend payment of ¥30.00 per share for the fiscal year ended March 31, 2025, resulting in an annual dividend of ¥50.00 per share. This decision reflects the company’s solid performance in its CRO business, despite increased expenses from the FDA approval of Satsuma’s STS101, and aligns with its policy of stable profit distribution.
The most recent analyst rating on (JP:2395) stock is a Hold with a Yen1460.00 price target. To see the full list of analyst forecasts on Shin Nippon Biomedical Laboratories, Ltd. stock, see the JP:2395 Stock Forecast page.
More about Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. operates in the biomedical industry, focusing on contract research organization (CRO) services. The company is committed to providing stable profit distributions to shareholders and aims for a payout ratio of 30-40% on a consolidated basis.
Average Trading Volume: 405,215
Technical Sentiment Signal: Sell
Current Market Cap: Yen55.75B
For a thorough assessment of 2395 stock, go to TipRanks’ Stock Analysis page.